PerkinElmer (NYSE:PKI) insider Daniel R. Tereau sold 1,156 shares of the business’s stock in a transaction dated Wednesday, April 18th. The shares were sold at an average price of $77.00, for a total value of $89,012.00. Following the completion of the sale, the insider now owns 6,784 shares in the company, valued at $522,368. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.
Shares of NYSE:PKI traded down $1.30 during midday trading on Thursday, reaching $75.10. The company had a trading volume of 408,401 shares, compared to its average volume of 667,614. The company has a debt-to-equity ratio of 0.71, a quick ratio of 0.89 and a current ratio of 1.26. The company has a market cap of $8,376.23, a P/E ratio of 25.90, a P/E/G ratio of 2.10 and a beta of 0.81. PerkinElmer has a 1-year low of $56.97 and a 1-year high of $84.49.
PerkinElmer (NYSE:PKI) last released its earnings results on Thursday, January 25th. The medical research company reported $0.97 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.94 by $0.03. The business had revenue of $641.63 million for the quarter, compared to the consensus estimate of $619.14 million. PerkinElmer had a return on equity of 13.30% and a net margin of 12.97%. PerkinElmer’s quarterly revenue was up 13.2% on a year-over-year basis. During the same quarter in the previous year, the business earned $0.83 earnings per share. equities analysts predict that PerkinElmer will post 3.52 earnings per share for the current fiscal year.
The business also recently announced a quarterly dividend, which will be paid on Thursday, May 10th. Investors of record on Friday, April 13th will be given a $0.07 dividend. This represents a $0.28 dividend on an annualized basis and a dividend yield of 0.37%. The ex-dividend date of this dividend is Thursday, April 12th. PerkinElmer’s dividend payout ratio is currently 9.66%.
A number of analysts have recently commented on PKI shares. Evercore ISI started coverage on PerkinElmer in a report on Wednesday, January 3rd. They issued an “in-line” rating and a $77.00 price target on the stock. Zacks Investment Research upgraded PerkinElmer from a “hold” rating to a “buy” rating and set a $86.00 price target on the stock in a report on Monday, January 8th. ValuEngine upgraded PerkinElmer from a “hold” rating to a “buy” rating in a report on Monday, April 2nd. Cowen restated a “hold” rating and issued a $84.00 price target on shares of PerkinElmer in a report on Friday, January 26th. Finally, Barclays boosted their price target on PerkinElmer from $69.00 to $73.00 and gave the company an “underweight” rating in a report on Friday, January 26th. One equities research analyst has rated the stock with a sell rating, ten have issued a hold rating and five have assigned a buy rating to the company. The company has an average rating of “Hold” and a consensus price target of $77.57.
Several large investors have recently added to or reduced their stakes in the stock. Elkfork Partners LLC acquired a new stake in shares of PerkinElmer in the fourth quarter valued at about $413,000. Xact Kapitalforvaltning AB acquired a new stake in shares of PerkinElmer in the fourth quarter valued at about $838,000. Envestnet Asset Management Inc. increased its position in shares of PerkinElmer by 17.0% in the fourth quarter. Envestnet Asset Management Inc. now owns 5,016 shares of the medical research company’s stock valued at $367,000 after acquiring an additional 729 shares during the last quarter. William Blair Investment Management LLC increased its position in shares of PerkinElmer by 12.5% in the fourth quarter. William Blair Investment Management LLC now owns 12,504 shares of the medical research company’s stock valued at $914,000 after acquiring an additional 1,390 shares during the last quarter. Finally, MetLife Investment Advisors LLC acquired a new stake in shares of PerkinElmer in the fourth quarter valued at about $2,493,000. 91.93% of the stock is currently owned by institutional investors and hedge funds.
TRADEMARK VIOLATION NOTICE: “Insider Selling: PerkinElmer (PKI) Insider Sells 1,156 Shares of Stock” was first published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this news story on another site, it was copied illegally and reposted in violation of US & international copyright law. The original version of this news story can be accessed at https://www.dispatchtribunal.com/2018/04/19/insider-selling-perkinelmer-pki-insider-sells-1156-shares-of-stock.html.
PerkinElmer Company Profile
PerkinElmer, Inc provides products, services, and solutions to the diagnostics, research, environmental, industrial, food, and laboratory services markets worldwide. The company operates in two segments, Discovery & Analytical Solutions and Diagnostics. The Discovery & Analytical Solutions segment develops and offers analytical technologies, solutions, and services for the environmental market that enable its customers to understand the characterization and health of various aspects, including air, water, and soil.
Receive News & Ratings for PerkinElmer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PerkinElmer and related companies with MarketBeat.com's FREE daily email newsletter.